Surrozen Inc
NASDAQ:SRZN

Watchlist Manager
Surrozen Inc Logo
Surrozen Inc
NASDAQ:SRZN
Watchlist
Price: 12.23 USD 15.76% Market Closed
Market Cap: 39.7m USD
Have any thoughts about
Surrozen Inc?
Write Note

Operating Margin
Surrozen Inc

-266.3%
Current
-131%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-266.3%
=
Operating Profit
-26.6m
/
Revenue
10m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Surrozen Inc
NASDAQ:SRZN
38.5m USD
-266%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
309B USD
28%
US
Amgen Inc
NASDAQ:AMGN
141B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
116B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
103.5B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
134.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
36B EUR
-22%
Country US
Market Cap 38.5m USD
Operating Margin
-266%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 309B USD
Operating Margin
28%
Country US
Market Cap 141B USD
Operating Margin
19%
Country US
Market Cap 116B USD
Operating Margin
38%
Country US
Market Cap 103.5B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 134.4B AUD
Operating Margin
26%
Country US
Market Cap 78.7B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 36B EUR
Operating Margin
-22%
No Stocks Found

Surrozen Inc
Glance View

Market Cap
39.7m USD
Industry
Biotechnology

Surrozen, Inc. is a preclinical stage biotechnology company, which engages in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The company is headquartered in South San Francisco, California and currently employs 83 full-time employees. The company went IPO on 2020-11-23. The firm is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. The firm's product candidates are multi-specific, antibody-based therapeutics that mimic the roles of naturally occurring Wnt or R-spondin proteins, which are involved in the activation and enhancement of the Wnt pathway. Its two technologies, Surrozen Wnt signal Activating Protein (SWAP) and Surrozen Wnt signal Enhancer Engineered for Tissue Specificity (SWEETS), enable to selectively modulate Wnt signaling through the generation of Wnt and R-spondin mimetics. SWAP molecules are designed to mimic the activity of naturally occurring Wnt proteins. SWEETS molecules are designed to amplify the body’s response to naturally occurring Wnt proteins. The firm's two lead product candidates include SZN-1326 and SZN-043.

SRZN Intrinsic Value
16.89 USD
Undervaluation 28%
Intrinsic Value
Price

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-266.3%
=
Operating Profit
-26.6m
/
Revenue
10m
What is the Operating Margin of Surrozen Inc?

Based on Surrozen Inc's most recent financial statements, the company has Operating Margin of -266.3%.